MW
LeonaBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lasofoxifene | ER+, HER2-negative, ESR1-mutated metastatic breast cancer | Phase 3 |
| ATH-1105 | Amyotrophic Lateral Sclerosis (ALS) | Phase 1 (inferred) |
| ATH-1020 | Undisclosed (Neurology) | Undisclosed |
| Fosgonimeton | Undisclosed (likely neurodegenerative) | Undisclosed |
Leadership Team at LeonaBio
ML
Mark Litton, PhD
President & Chief Executive Officer
JS
Javier San Martin, M.D.
Chief Medical Officer
KC
Kevin Church, PhD
Chief Scientific Officer
RR
Robert Renninger
Chief Financial Officer
KR
Kelly Romano
Chair of the Board of Directors
JE
Joseph Edelman
Board of Directors